Multiple System Atrophy Market Analysis

The market is segmented by diagnosis into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test, and others, out of which, the magnetic resonance imaging (MRI) segment is anticipated to hold the largest share in the global multiple system atrophy (MSA) market on account of the high usage of MRI techniques for differentiation of systemic atrophy with Parkinson’s disease, and its usefulness in tracking the progression of multiple system atrophy. Along with this, the segment for tilt table test is also predicted to occupy a significant market share during the forecast period owing to the rising use of this test to document the extent of blood pressure irregularities, which is fundamental for diagnosing systemic atrophies.

Our in-depth analysis of the global multiple system atrophy (MSA) market includes the following segments:

By Type	Parkinsonian Cerebellar
By Diagnosis	Magnetic Resonance Imaging (MRI) Positron Emission Tomography (PET) Single Photon Emission Computed Tomography (SPECT) Tilt Table Test Others

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of multiple system atrophy is assessed at USD 144.42 million.

Multiple System Atrophy (MSA) Market size was over USD 139.4 million in 2023 and is anticipated to reach USD 247.04 million by 2036, growing at around 4.5% CAGR during the forecast period i.e., between 2024-2036. The market growth is impelled by growing occurrence of multiple system atrophy across the world and increasing research and development activities to develop effective treatment for systemic atrophies.

Asia Pacific is set to account for largest revenue share by 2036, on the back of increasing number of cases of multiple system atrophy, especially in Japan, high patient pool and growing government initiatives to improve the infrastructure of healthcare in the region.

The major players in the market are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, and others.

Multiple System Atrophy Market Analysis